24/7 Wall St. » BRL

Top 10 Pre-Market Analyst Calls (BRL, BE, EDS, HPQ, IRM, MHP, MCO, RSH, SNH, SNN, SOV)

247wallst — Tue, 13 May 2008 06:40:21 +0000

These are not the only analyst calls this morning, but these are some of the impact calls we are seeing this Tuesday morning:

Barr Pharma (NYSE: BRL) raised to Outperform from Neutral at Cowen & Co.
Bearingpoint (NYSE: BE) Cut to Hold from Buy at Citigroup
Electronic Data Systems (NYSE: EDS) Cut to Sell from Hold at Citigroup; cut to Market Perform at FBR.
Hewlett-Packard Co. (NYSE: HPQ) was removed from the Goldman Sachs Conviction Buy List, although its BUY rating was maintained.
Iron Mountain (NYSE: IRM) Started as Neutral at Credit Suisse.
McGraw-Hill (NYSE: MHP) and Moody’s (NYSE: MCO) both started as Buy in new coverage at Jefferies.
RadioShack (NYSE: RSH) raised to Market Perform at RBC.
Senior Housing Properties (NYSE: SNH) Cut to Market Perform from Outperform at Raymond James.
Smith & Nephew (NYSE: SNN) Cut to Underweight from Neutral at JPMorgan.
Sovereign Bancorp (NYSE: SOV) Raised to Market Perform at FBR.

Jon C. Ogg
May 13, 2008

The 52-Week Low Club (BRL)(TSO)(PLA)(SDBT)(HANS)(ARNA)

247wallst — Thu, 08 May 2008 14:59:44 +0000

Barr Pharmaceuticals (BRL) Says business pace is falling off. Down to $37.40 from 52-week high of $58.38.

Tesoro Corporation (TSO) Broker downgrade. Dips to $22.92 from 52-week high of $65.98.

Playboy Enterprises (PLA) Earnings weaken. Falls to $7.01 from 52-week high of $12.

Soundbite Communications (SDBT) Analyst downgrade. Falls to $2.44 from 52-week high of $8.25.

Hansen Natural (HANS) Earnings miss estimates. Sells off to $28.51. from 52-week high of $68.40.

Arena Pharmaceuticals (ARNA) Misses on earnings. Dips to $4.92 from 52-week high of $14.78.

Douglas A. McIntyre

Lowering the Barr (BRL)

247wallst — Thu, 08 May 2008 08:51:56 +0000

Who thought generics could ever look so bad? This morning, Barr Pharmaceuticals (NYSE: BRL) has posted very poor numbers.

The company posted $0.57 EPS, far under the First Call consensus of $0.79. Revenues rose 1.8% year over year to $608 million, while $684.1 million was the consensus estimate. To make matters worse, its mixed guidance for Fiscal 2008 was put at $2.75 to $3.05 EPS. This is under the $3.27 consensus estimate and down from previous range of $3.05-$3.35 EPS for the year. The company did keep 2008 revenues in a range of $2.7 to $2.8 billion, and First Call had estimates of $2.78 Billion.

Barr noted that the reduction to its poor results was on U.S. generic revenue coming in lower than expected. The company also noted that it does not expect this to be completely offset by the expected launch of its generic birth control pill in 2008.

Brand name drug sales are seeing issues almost weekly, the pressure is on to lower healthcare costs, and somehow generic sales are weak. Is the economic weakness to the point that people decided they can’t afford their co-pay rates?

Based on the crummy report, no one is giving the company the benefit of the doubt. Shares are now at a new 52-week low this morning. Shares are down more than 20% at $38.50 in early trading. Its prior 52-week trading range was $45.33 to $58.38.

To make matters worse, the company broke its stock chart too.

Jon C. Ogg
May 8, 2008

Top 10 Pre-Market Analyst Calls (ADBE, CRUS, DVA, EEQ, EQR, IP, LNCR, RGLD, WIN, BRL, MFLX, MYL, TEVA, WPI)

247wallst — Tue, 18 Dec 2007 07:59:00 +0000

These are not the only analyst impact calls, but these are the top research notes that 247WallSt.com is focusing on:

Adobe Systems (ADBE) raised to Buy at Deutsche Bank.
Cirrus Logic (CRUS) raised to Buy at Jefferies.
DaVita (DVA) raised to Buy at Oppenheimer.
Embarq (EQ) raised to Overweight at J.P.Morgan.
Equity Residential (EQR) raised to Overweight at Lehman.
International Paper (IP) raised to Outperform at Credit Suisse.
Lincare (LNCR) downgraded to Neutral at Oppenheimer.
Royal Gold (RGLD) raised to Overweight at HSBC.
Windstream (WIN) downgraded to Underweight at J.P.Morgan.
BANC OF AMERICA ON DRUGS: Barr Pharma (BRL) started as Buy; Multi-Fineline (MFLX) started as Buy; Mylan Labs (MYL) started as Buy; Teva Pharma (TEVA) started as Buy; Watson Pharma (WPI) started as neutral; ZymoGenetics (ZGEN) downgraded to Neutral.

Jon C. Ogg
December 18, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he produces the SPECIAL SITUATION newsletter and he does not own securities in the companies he covers.